Argus raised the firm’s price target on Merck to $140 from $120 and keeps a Buy rating on the shares. The company continues to receive regulatory approvals for expanded or additional indications for its products, including further indications for major revenue generator Keytruda and an approval for Welireg for the treatment of certain adult patients with advanced renal cell carcinoma, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- BioXcel Therapeutics completes patient enrollment in Phase 2 trial of BXCL701
- M & A News: Merck (NYSE:MRK) Snaps Up Elanco’s Aqua Unit for $1.3B
- Elanco to sell aqua business to Merck for $1.3B in cash
- Merck Animal Health to acquire Elanco’s aqua business for $1.3B in cash
- Senate Health, Education, Labor & Pensions Committee holds a hearing
